PLAY PODCASTS
U.S. Risking its Scientific Research Edge?
Episode 169

U.S. Risking its Scientific Research Edge?

Stanford Law’s Lisa Ouellette discusses the rollback of federal support for vital academic research, the challenge of defending U.S. research from political interference, and ensuring drug development meets real-world health needs

Stanford Legal

August 21, 202531m 9s

Audio is streamed directly from the publisher (op3.dev) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode of Stanford Legal, host Professor Pamela Karlan interviews her Stanford Law School colleague Professor Lisa Larrimore Ouellette about actions by the Trump administration that Ouellette says are undermining scientific research and jeopardizing America’s longstanding global leadership in medicine and innovation. Drawing on an essay she penned for Just Security, Ouellette explains how decades of bipartisan support for federally funded science—an engine of American innovation since World War II—is now at risk. From canceling grants already approved through peer review, to capping essential “indirect cost” reimbursements, she details how these moves threaten not just labs and universities but also patients, whose clinical trials are being abruptly halted.  

Ouellette also highlights a second front in her current scholarship: how drug development policy can be better aligned with public health needs. As a member of a National Academies committee, she recently co-authored a report showing that both private investment and federal funding often fail to prioritize diseases causing the greatest suffering. 

Links:

Connect:

(00:00) Research Funding 

(05:01) The Competitive Grant Process 

(15:01) Addressing Disease Burden 

(20:00) Impacts of Stopped Clinical Trials 

(25:01) The Role of Federal Investment in Innovation 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

innovationtrump administrationsouthern district of new yorkpam karlannational science foundationgrant proposalsinvestment prioritiesjust securityintellectual propertyresearch fundinglisa larrimore ouellettepublic healthdisease burdenclinical trialsdiversityindirect costsnational institutes of healthmrna technologyfederal court of claimsvaccine researchtherapeutic developmentequitybasic sciencepeer review processmarket forcesfunding allocationsfederal investmentand inclusionunmet medical needs